rHuEPO Hyporesponsiveness and Related High Dosages Are Associated with Hyperviscosity in Maintenance Hemodialysis Patients

Table 1

Demographic and biochemical characteristics of the whole study group.

	Study group (𝑛=84)
Age (years)	54.88±13.7
Gender (F/M)	30/54
Mean plasma viscosity (mPas)	2.52±0.65
MHD duration (months)	115.41±81.72
Mean serum Hb level (g/dL)	11.28±1.53
Mean serum WBC count (/µL)	7.40±1.84
Mean serum Plt count (/µL)	215.89±64.35
Median serum PTH level (pg/mL)	397.85 (498.30)
Mean serum Ca level (mg/dL)	9.31±0.65
Mean serum P level (mg/dL)	4.95±1.00
Mean Ca × P product	46.41±10.80
Mean serum CRP level (mg/L)	16.28±11.28
Mean serum albumin level (g/dL)	3.64±0.35
Median serum ferritin level (ng/mL)	531.00 (331.50)
Total parenteral iron therapy (U/12 months)	20000 (3000)
Total rHuEPO usage (U/kg/week)	295.00 (422.35)
rHuEPO/Hb	25.49±20.48